A B S T R A C T Propylthiouracil (PTU) inhibits peripheral deiodination of thyroxine (T4) and triiodothyronine (T3) and decreases the metabolic effectiveness of T4 in animals. To assess the effect of PTU on extrathyroidal conversion of T4 to Ta in man, 15 studies were performed in 7 athyreotic patients treated with 100 or 200 Ag of L-T4 daily for 1 mo before the addition of PTU, 250 mg every 6 h for 8 days. Serum T3, T4, and thyrotropin (TSH) were measured daily by radioimmunoassay; serum TSH response to 500-ig thyrotropin-releasing hormone (TRH) was measured before and on the last day of giving PTU.
INTRODUCTION
Antithyroid drugs of the thiocarbamide type, such as propylthiouracil (PTU),1 have been used for the treatment of hyperthyroidism for over 30 yr. PTU appears to exert its primary effect on the synthesis of the thyroid hormones, thyroxine (T4) and triiodothyronine (Ts), by blocking oxidative iodination within the thyroid gland itself (1, 2) . In addition, some of the thiocarbamides alter the metabolism of thyroid hormones outside of the thyroid gland by interfering with the peripheral deiodination of T4 and Ts in experimental animals (3) (4) (5) (6) (7) (8) (9) (10) and in man (10) (11) (12) (13) . This extrathyroidal action is independent of the first effect (14) . The inhibition of peripheral deiodination is associated with a decrease in the biologic effectiveness of administered T4 as measured by a decrease in metabolic rate or induction of oxidative enzymes in vivo (15) (16) (17) (18) (19) (20) and in vitro (21) (22) (23) and an increase in thyrotropin (TSH) secretion (24) (25) (26) (27) (28) . The thiocarbamide drugs that decrease To deiodination are the ones that also decrease its metabolic effectiveness (14) . These same drugs also decrease Ts deiodination but have no effect on the biologic effectiveness of T3 or actually potentiate it (5, 14, 19) .
Since the reintroduction of the concept that a sig-I Abbreviations used in this paper: CPB, competitive protein binding; PBI, protein-bound iodine; PTU, propylthiouracil; RIA, radioimmunoassay; TRH, thyrotropinreleasing hormone; TSH, thyrotropin; T,, triiodothyronine; T4, thyroxine.
The Journal of Clinical Investigation Volume $5 February 1975-224-229 nificant amount of T8 is produced by the peripheral deiodination of T4 (29) , interest has arisen in the clinical effects of PTU on the peripheral metabolism of T4. Oppenheimer, Schwartz, and Surks (23) have demonstrated that PTU decreases the calculated rate of conversion of T4 to Ts in thyroidectomized T4-treated rats. We have investigated the effect of PTU on the serum concentrations of T3, T4, and TSH, and the TSH response to thyrotropin-releasing hormone (TRH) in athyreotic patients maintained on L-T4. METHODS Subjects. 16 studies were carried out on 7 totally athyreotic male patients. Six patients had had total surgical thyroidectomies followed by ablative doses of radioactive iodine, and one patient had idiopathic myxedema. Proof of the athyreotic state was based on lack of significant radioiodine uptake and no evidence of its accumulation on scan, serum T4 less than 1 /Ag/dl and T3 less than 50 ng/ dl, and lack of T4 or T3 elevation in response to the TRHmediated rise of serum TSH concentration.
Three patients had atherosclerotic cardiovascular disease, one of whom was taking digoxin during the time of study. One patient had a transitional cell carcinoma of the bladder resected a year before the study with no evidence of recurrence or of renal insufficiency. One patient had Parkinson's disease and was taking L-dopa and trihexyphenidyl hydrochloride during the study. None of the others was taking any medication known to affect thyroidal or pituitary function. The patients gave their informed consent to participate in the studies.
All patients were treated daily with 100 lug of a commercial preparation of sodium levothyroxine (L-T4) for at least 1 mo before admission to the metabolic unit. In addition, five of the patients were restudied after they had been taking 200 ug of L-T4 daily for at least 1 mo. A single commercial preparation of L-T4 (lot ZE040) was kindly supplied by Flint Labs., Morton Grove, Ill., and used throughout the study. The T3 content was 0.76% (by weight) of the T4 content.
Bloods were collected daily for determination of serum TSH, T4, and T3 during hospitalization. The patients' white cell counts and liver function were also monitored. After a control period of several days to determine basal concentrations, the L-T4-treated patients were given PTU, 250 mg every 6 h, for 8 days. TSH, T4, and T3 concentrations were also determined before, and on the 7th day of, PTU treatment at 2, 6, 10, and 14 h after administration of the L-T4 dose. TRH testing of pituitary TSH responsiveness was carried out at least once before, and on the last day of, PTU administration.
Serum determinations. T3 (30) and TSH (31) were measured by radioimmunoassay (RIA). T4 was determined by both RIA (32) and competitive protein binding (CPB) (33) . Protein-bound iodine (PBI) (done by Bio-Science Laboratories, Van Nuys, Calif.), total protein, albumin. and T3 resin index (using the Thyopac-3 of Amersham/Searle Corp., Arlington Heights, Ill.) were determined on selected sera.
Infusions. Synthetic TRH was kindly supplied by Abbot Laboratories, North Chicago, Ill. It was administered in the morning after an overnight fast. A 19-guage butterfly needle was inserted in an antecubital vein for collection of blood specimens 15 min before, at the time of, and 15, 30, 45, 60, 120, and 240 min after injection of a 500-jug bolus of TRH. Statistics. Change in serum concentrations of T3, T4, and TSH were evaluated for significance by the method of paired t testing (34) . RESULTS
Effect of PTU on T., T4 and TSH. Fig. 1 Effects of PTU on TSH response to TRH. Fig. 4 shows the TSH response to TRH during eight studies carried out in the patients taking 100 Ag of L-T4 a day.
Expressed as a percent of initial TSH concentrations, the TSH response in the control period compared with the response during PTU administration was signifi- The fall in serum T3 derived exclusively from administered To is consistent with the PTU-induced decrease in total deiodination of T4 previously described in experimental animals (3-10) and in man (10) (11) (12) (13) (10) (11) (12) (13) (14) . Another mechanism to explain our findings might be that PTU increases the metabolic clearance of T8. Oppenheimer et al. (23) showed that PTU reduced the calculated rate of conversion of T4 to T3 in thyroidectomized rats and also reduced the fractional rate of deiodination of both T3 and T4. To conclusively establish the mechanism for the reduction of serum T3 induced by PTU in man, direct kinetic analysis of T4 and T3 metabolism must be carried out.
The PTU-induced decrease in the peripheral deiodination of T4 to T3 has been shown to be associated with a decrease in biologic activity of T4 in vivo (15) (16) (17) (18) (19) (20) and in vitro (21) (22) (23) . Methimazole and other thiocarbamide drugs which do not affect the deiodination of To do not interfere with its metabolic effectiveness (14) . This extrathyroidal effect of PTU probably contributes to its effectiveness in the treatment of hyperthyroidism. Abuid and Larsen (35) demonstrated a significantly greater fall in T3 concentration and T3/T4 ratio in hyperthyroid patients being treated acutely with PTU plus iodine compared with those treated with methimazole plus iodine suggesting that the inhibition of Ti to T3 conversion by PTU may play a significant role in its therapeutic effectiveness.
We did not measure absolute free thyroid hormone concentrations. However, it has been shown previously that PTU has no effect on thyroid hormone binding to human plasma proteins (10, 13). There was no significant change in T, resin uptake or plasma protein concentration during PTU administration in our patients.
The increase in basal concentrations of serum TSH and the increased TSH response to TRH associated with the decrease in serum T3 is of great interest. It occurred at a time when there was no significant change in serum T4 concentration. Previous investigators have shown that PTU administration increased the amount of bioassayable TSH in the serum of thyroidectomized to TRH at a time when in some patients serum T4 is elevated but T3 has fallen to normal concentrations (42) . Our findings are consistent with these observations. In our patients presumed blockade of deiodination of the administered L-T4 to T3 resulted in increasing serum TSH concentration and augmentation of the TSH response to TRH at a time when serum T3 concentration fell, but T4 concentration remained unchanged. The TSH response was relatively consistent in those patients who were tested with TRH on two occasions before administration of PTU. Thus the larger response during administration of PTU is not attributable to the previous test with TRH.
We cannot completely exclude a direct stimulatory effect of PTU on TSH release by the pituitary. Bioassay data concerning the effect of thiocarbamides on thyroid hormone suppression of TSH release from the pituitary indicate that, although PTU decreases the effectiveness of a given dose of L-T4, it has no effect on the ability of L-T8 to suppress TSH release (14) . Therefore we suggest that the augmentation in basal TSH level and the TSH response to TRH in our patients was most likely due to the fall in serum T3 concentration caused by the effect of PTU on blocking the peripheral conversion of T4 to T3. Our data are consistent with the hypothesis that Ts is more important than T, for modulation of pituitary TSH secretion.
Addendum. Saberi, Sterling, and Utiger (43) have recently presented findings similar to those reported here.
